Please wait
Healthcare · Drug Manufacturers - General · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
$32.3B
N/A
38.74
Current price
$218.32
-0.1% todayUpdated just now
Open
$221.17
Previous close
$218.50
Day range
$213.58 – $222.00
Volume
N/A
38.7x P/E
Awaiting filing
No current yield
65/100 measured
Easy to trade
Recent price movement, key market context and the latest company information.
The latest saved price history for BIIB, with its range and direction at a glance.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Investors usually follow BIIB for its valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 68/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
$97.5M
TTM (2026-06-30)
ROE
4.6%
Return on equity
ROA
5.2%
Return on assets
Debt / equity
0.44
Lower is usually safer.
P/B ratio
1.71
Useful for book value support.
85/100
Direction
Range-bound
Main supports
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Volatility is elevated, so the path can stay rough even if the thesis is right.
Fair value
$227.36
Analyst view
Buy
Analyst target
$236.22
Forecast refresh
Updated just now
Quality score
67
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+7.6% across the latest saved price window.
Volatility
Low
Beta is 0.16. Price has historically moved more calmly than the wider market.
52-week position
95% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
BIIB
Biogen Inc.
Price: $218.32
P/E: 38.741135
Yield: N/A
ABBV
AbbVie Inc.
Price: $256.22
P/E: 72.994286
Yield: 2.7%
ABT
Abbott Laboratories
Price: $110.02
P/E: 36.39806
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: $158.16
P/E: 27.310226
Yield: 0.0%
Industry
Drug Manufacturers - General
Employees
7500
Exchange
NMS
Ticker
BIIB
